Vital exhaustion predicts long-term risk for adverse cardiac events in men and women, independent of established biomedical risk factors.
A new three-drug antihypertensive pill, combining an angiotensin II receptor antagonist (olmesartan [OLM]), a calcium channel blocker (amlodipine [AML]), and a thiazide diuretic (hydrochlorothiazide [HCTZ]), has been approved by the FDA. The new combination is marketed by Daiichi Sankyo as Tribenzor.
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
In a sample of patients from primary care practice, a single screening question accurately identified drug use.
Replacing saturated fatty acids with carbohydrates with low glycemic index values is associated with a lower risk of myocardial infarction.
More than three-fourths of men have some degree of male pattern hair loss by age 70. The unwanted hair loss seen in male pattern hair loss is stimulated by dihydrotestosterone.
